MSH3 and cancer: Although the EMAST biomarker is inclusive among MSI-H colorectal cancers due to the complete absence DNA mismatch repair, it, as a stand-alone biomarker with isolated MSH3 dysfunction, shows a different clinicopathogenic portfolio when compared to MSI-H cancers (Table 3).